RSV Seasonal Vaccine Introduction and Growth Strategy
68 potential new vaccines and medicines in pipeline
Phase-32 assets
2904545
4429016
3993129
4382276
4396687
4077164
3943104
3536867
2556286
3186899
3494245
3772701
3882347
3923868
4182137 (VIR-7832)
3965193
5251738
cabotegravir (1265744)
3739937
Recombinant protein, adjuvanted*
Bioconjugated recombinant protein, adjuvanted*
Adjuvanted recombinant subunit
mRNA*
mRNA*
Bivalent GMMA*
Recombinant protein, adjuvanted*
Bivalent conjugate*
Mtb cholesterol dependent inhibitor*
CRK-12 inhibitor*2
Proteasome inhibitor*
P. falciparum whole cell inhibitor*
FimH antagonist*
PI4K beta inhibitor
Anti-spike protein antibody*
PAPD5/PAPD7 inhibitor
TLR8 agonist*
Integrase inhibitor (400 mg/ml formulation)
Maturation inhibitor
Capsid protein inhibitor
Capsid protein inhibitor
Integrase inhibitor*
4004280
4011499
4524184
3888130
Anti-IL7 antibody*
1070806
Anti-IL18 antibody
4527226 (AL-101)
4074386
4381562
3745417
6097608
XMT-20563
(wholly owned by Mersana Theraprutics)
belantamab (2857914)
4172239
Anti-sortilin antibody*
Anti-LAG-3 antibody*
Anti-PVRIG antibody*
STING agonist
Anti-CD96 antibody*
STING agonist ADC*
Anti-BCMA antibody
DNMT1 inhibitor*
C. difficile
K. pneumoniae
Cytomegalovirus'
Seasonal flu
COVID-19
Invasive non-typhoidal salmonella**
Therapeutic herpes simplex virus
Salmonella (typhoid + paratyphoid A)
Tuberculosis
Visceral leishmaniasis
Visceral leishmaniasis
Malaria
Uncomplicated UTI
Viral COPD exacerbations
COVID-191
Hepatitis B virus'
Hepatitis B virus
HIV
HIV
HIV
HIV
HIV
Multiple sclerosis
Atopic dermatitis
Alzheimer's disease
Cancer
Cancer
Cancer
Cancer
Cancer
Multiple myeloma
Sickle cell disease
Infectious diseases
HIV (VIIV)
Respiratory/Immunology
Oncology
Opportunity driven
GSK
*In-license or other alliance relationship with third party
**
Additional indications or candidates also under investigation In registration
1. In phase I/II study 2. Transition activities underway to enable further progression by partner 3. GSK has an exclusive global license option to co-develop and commercialise the candidate 4. Imminent study start 5. GSK has
exclusive option to co-develop post phase II 6. Phase II/III study start expected in 2023 7. Phase II study start expected in 2023 8. Approved in US and EU 9. Phase III study start expected in 2023 10. Phase III trial in patients
with progranulin gene mutation
37
32View entire presentation